US equities
|
SPCX
$166.79
▲+4.93%
NVDA
$236.81
▲+1.22%
MU
$1,063.33
▼-1.08%
TSLA
$377.10
▲+1.76%
MSFT
$525.23
▲+1.49%
SNDK
$1,708.07
▼-0.69%
INTC
$117.19
▼-1.79%
META
$743.51
▲+2.12%
SPCX
$166.79
▲+4.93%
NVDA
$236.81
▲+1.22%
MU
$1,063.33
▼-1.08%
TSLA
$377.10
▲+1.76%
MSFT
$525.23
▲+1.49%
SNDK
$1,708.07
▼-0.69%
INTC
$117.19
▼-1.79%
META
$743.51
▲+2.12%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Edgewise Therapeutics, Inc. - Common Stock
(NQ:
EWTX
)
41.30
-0.10 (-0.24%)
Delayed Quote
Updated: 12:03 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Edgewise Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 13, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 09, 2025
From
Pomerantz LLP
Via
GlobeNewswire
Edgewise Therapeutics Inc (NASDAQ:EWTX) Q2 2025 Earnings: EPS Beat Sparks 5% Pre-Market Rally
↗
August 07, 2025
Edgewise Therapeutics (EWTX) reports Q2 2025 EPS beat at -$0.34 vs. -$0.42 estimates, sparking a 5% pre-market rally. Clinical progress in muscle disease treatments drives optimism.
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 05, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
August 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 23, 2025
From
Pomerantz LLP
Via
GlobeNewswire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
July 19, 2025
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 18, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 14, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 10, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 03, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
July 01, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 30, 2025
Via
ACCESS Newswire
This Starbucks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
June 30, 2025
Via
Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 28, 2025
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Edgewise Therapeutics, Inc. - EWTX
June 26, 2025
Via
ACCESS Newswire
No Accelerated FDA Approval For Edgewise's Rare Muscular Disease Drug; Shares Fall
↗
June 26, 2025
Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2 trial data.
Via
Benzinga
Top movers in Friday's after hours session
↗
May 23, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
May 12, 2025
Via
Benzinga
Why Edgewise Therapeutics Stock Popped This Week
↗
May 02, 2025
Via
The Motley Fool
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
April 21, 2025
Via
Benzinga
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2
↗
April 10, 2025
Via
Benzinga
Top movers in Wednesday's session
↗
April 02, 2025
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via
Chartmill
These stocks are moving in today's session
↗
April 02, 2025
Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's Intraday Session
↗
April 02, 2025
Via
Benzinga
Traders are paying attention to the gapping stocks in Wednesday's session.
↗
April 02, 2025
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.
Via
Chartmill
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study
↗
April 02, 2025
Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is expected in late 2025.
Via
Benzinga
These stocks are moving in today's pre-market session
↗
April 02, 2025
The US market session of Wednesday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via
Chartmill
Why Edgewise Therapeutics (EWTX) Stock Is Falling
↗
April 02, 2025
Edgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $200 million offering.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
